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Abstract: Osteosarcoma is the most frequent malignant primary bone tumor characterized by a high
potency to form lung metastases. In this study, the effect of three oversulfated low molecular weight
marine bacterial exopolysaccharides (OS-EPS) with different molecular weights (4, 8 and 15 kDa) were
first evaluated in vitro on human and murine osteosarcoma cell lines. Different biological activities
were studied: cell proliferation, cell adhesion and migration, matrix metalloproteinase expression.
This in vitro study showed that only the OS-EPS 15 kDa derivative could inhibit the invasiveness
of osteosarcoma cells with an inhibition rate close to 90%. Moreover, this derivative was potent to
inhibit both migration and invasiveness of osteosarcoma cell lines; had no significant effect on their
cell cycle; and increased slightly the expression of MMP-9, and more highly the expression of its
physiological specific tissue inhibitor TIMP-1. Then, the in vivo experiments showed that the OS-EPS
15 kDa derivative had no effect on the primary osteosarcoma tumor induced by osteosarcoma cell
lines but was very efficient to inhibit the establishment of lung metastases in vivo. These results can
help to better understand the mechanisms of GAGs and GAG-like derivatives in the biology of the
tumor cells and their interactions with the bone environment to develop new therapeutic strategies.
Keywords: exopolysaccharides; glycosaminoglycan; heparin-like; derivatives; sulfation; bone
metabolism; bone remodeling; lung mestatases; osteosarcoma
1. Introduction
Osteosarcoma is the most frequent malignant primary bone tumor that occurs mainly in the
young, with an incidence peak observed at 18 years. Despite recent improvements in chemotherapy
and surgery, the problem of non-response to chemotherapy remains and this poor prognosis warrants
new therapeutic strategies to improve the overall rate of survival. The osteosarcoma is characterized
by a high potency to form lung metastases that is the main cause of death [1,2]. Recent studies have
described the molecular mechanisms of metastasis occurrence that can help to identify new therapeutic
strategies [3]. Carbohydrates and especially heparin or heparan sulfate are now considered as good
candidates to treat cancers, in particular cancer metastasis, but nevertheless their therapeutic use is
limited because they present both anticoagulant activity and consequently they can induce adverse
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bleeding complications. Further disadvantages of heparin and heparan sulfate are their animal origin
with a high risk of unknown cross-species contamination [4,5]. Consequently, the exploration of the
therapeutic potential of heparin mimetics is now booming. Sulfated oligosaccharides are currently
studied such as a sulfated form of phosphomannopentaose and phospohomannotetraose named
PI-88 [6], sulfated form of maltohexose and sulfated maltotriose [7]. Recently, two polysaccharides
extracted from Prunella vulgaris L. were described for their anti-lung adenocarcinoma activity [8].
In recent years, there has been a growing interest in the isolation and identification of new
microbial polysaccharides that might have new uses in many industries. They compete with
polysaccharides from other sources such as seaweeds, crustaceans, animals or plants. Interest in
mass culture of microorganisms from the marine environment has increased considerably, representing
an innovative approach to the biotechnological use of under-exploited resources. When sulfated,
polysaccharides from different sources can share some biological properties with glycosaminoglycans
and especially heparan sulfate or heparin without presenting the same bleeding risk and with a low
risk to be contaminated by a non-conventional transmissible agent such as prions or emerging viruses
due to a large “species-barrier” [9].
Marine bacteria associated with deep-sea hydrothermal conditions have demonstrated their ability
to produce, in an aerobic carbohydrate-based medium, unusual extracellular polymers. They present
original structural features that can be modified to design bioactive compounds and improve their
specificity [10,11]. In particular, with the aim of promoting biological activities, chemical modifications
(depolymerization and substitution reactions) of one exopolysaccharide (GY785 EPS) produced by a
deep-sea hydrothermal bacterium named Alteromonas infernus have been undertaken. A low molecular
weight (LMW) oversulfated derivative (OS-EPS) has been isolated after chemical modifications of this
native GY785 EPS. This derivative is less efficient (10 fold) than heparin in clotting assays. In activated
partial thromboplastin time, the same anticoagulant effect was obtained at 10 µg/mL and 1.5 µg/mL
of OS-EPS derivative and heparin, respectively [12]. The structure of the native GY785 EPS has been
described [13].
The growth and differentiation of bone cells is controlled by various factors that can be modulated
by heparan sulfates. The heparan sulfate effect is not only charge dependent but also chain length
dependent. The results of clinical trials indicated that LMW GAGs had less effect on bone formation
than unfractionated GAG [5]. The effects of the derivative named OS-EPS on bone biology have been
previously studied. The effect of this highly sulfated LMW derivative (40% sulfate groups and 24 kDa)
has been compared with that of a non-oversulfated LMW GY785 EPS (10% sulfate groups and 13 kDa).
The observed data have shown different levels of bone resorption regulation by GAGs or OS-EPS,
most of them leading to pro-resorptive effects [14].
The chain length impact of OS-EPS derivatives on several kinds of biological activities was
investigated here to determine which size could be the most effective on bone tumor growth model.
First, in some in vitro experiments, we compared the activity of three OS-EPS derivatives with various
molecular weights (4, 8 and 15 kDa) on osteosarcoma cell lines (mouse POS-1 and human HOS
cells), and using heparin as a reference. Proliferation, migration, cell cycle analysis and expression in
osteosarcoma cell lines of matrix metalloproteinases such as gelatinases MMP-2 and MMP-9 and their
inhibitors TIMP-1 and TIMP-2 were studied. Then, the OS-EPS derivative (OS-EPS 15 kDa) showing
the most interesting properties in vitro was evaluated in vivo on both primary malignant bone tumor
growth (paratibial model) and establishment of lung metastases in osteosarcoma mouse model, and
again heparin was used as a reference.
2. Results and Discussion
2.1. Characterization of OS-EPS Derivatives
The molecular weight, polydispersity and chemical composition of each derivative are presented
in Table 1. LMW OS-EPS derivatives were homogeneous with a low polydispersity. After the chemical
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oversulfation, no important change in their respective initial osidic composition was observed. The
OS-EPS derivatives had a sulfur content above 10%, corresponding to above 30% of sulfate groups
close to that found in heparin.
Table 1. Molecular weight and chemical composition of the oversulfated exopolysaccharide
(OS-EPS) derivatives.
EPS Derivatives Mw * g/mol Mn * g/mol I * Mw/Mn S ** % Neutral Sugars *** % Acidic Sugars **** %
OS EPS GYS15 16000 14000 1.14 15 18 10
OS EPS GYS8 10000 8000 1.25 13 19 12
OS EPS GYS4 5300 4700 1.13 14 23 11
* Mw = weight average molecular mass, Mn = number average molecular mass, I = polydispersity index
(Mw/Mn); ** Sulfur was determined by elemental analyzer and HPAEC chromatography; *** Method of Dubois
et al. (1956) and **** Method of Filisetti-Cozzi and Carpita (1991).
2.2. In Vitro Effect of OS-EPS on Osteosarcoma Cell Lines
2.2.1. Cell Proliferation and Cell Viability
Compared to the controls, only OS-EPS 4 kDa and 15 kDa derivatives significantly inhibited both
mouse POS-1 and human HOS cell proliferation. The most potent OS-EPS derivative to inhibit the
proliferation of osteosarcoma cell lines was the OS-EPS 4 kDa (Figure 1A). After three days of treatment
with GYS15 no significant effect was shown on HOS cell proliferation or cell viability in contrast to
GYS4 (Figure 1B). After seven days of treatment, 25 µg/mL of GYS15 markedly decreased the HOS cell
proliferation (Figure 1C). These data are in agreement with those obtained on osteoblastic cells [14].
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Figure 1. Comparison of the effects of OS-EPS derivatives with various molecular weights on two
osteosarcoma cell lines, the mouse POS-1 and human HOS: (A) proliferation of both cell lines after seven
days of treatment; (B) cell viability assessment of HOS and POS-1 cells after three days of treatment
with or without OS-EPS derivative treatment; and (C) kinetic of biological activity of increasing doses
of GYS15 on HOS cell proliferation. Proliferation assays were performed by cell counting with Trypan
Blue to compare the cell proliferation rate between groups. OS-EPS 15 kDa (GYS15), OS-EPS 8 kDa
(GYS8), OS-EPS 4 kDa (GYS4), heparin (Hep) and control (CT). * p < 0.05; ** p < 0.01; *** p < 0.001.
2.2.2. Cell Migration Assay
We investigated the effects of OS-EPS derivatives on the osteosarcoma cell migration using an
in vitro wound-healing assay. All compounds assessed (OS-EPS4, OS-EPS8, OS-EPS15 and heparin)
inhibited the migration of murine POS-1 osteosarcoma cells (data not shown). In contrast to this cell
line, only OS-EPS 4 and 15 kDa were potent to inhibit the migration of human HOS osteosarcoma
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cells (Figure 2). Indeed, OS-EPS 15 kDa derivative strongly slowed down the migration of HOS cells
compared to the other compounds.Molecules 2016, 21, 309 4 of 13 
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Figure 2. Migration of the human HOS cells and mouse POS-1 cells in the presence of various OS-EPS
derivatives (300 µg/mL): OS-EPS 15 kDa (GYS15), OS-EPS 8 kDa (GYS8), OS-EPS 4 kDa (GYS4),
heparin and control (CT). This experiment was repeated three times and a representative experiment
is shown.
It is admitted that heparin, hich is conventionally administered as n anticoagulant, has
a variety f additional biological activities especially on cancer cells [15,16]. I vitro and in vivo
experimental evidence demonstrated that heparin is an efficient inhibitor of cell migration, adhesion
and metastasis [15]. Common molecular pathways with platelet-tumor cell thrombi formation such
as the inhibition of heparanase or P-/L-selectin may be involved in this activity [17]. In contrast to
heparin, OS-EPS derivatives assessed in the present work inhibited the cell migration of osteosarcoma,
suggesting a mech nism of action independent of heparanase and s lectin. Mechan sms associated
with inhibition of integrin activity can be hypothesized [18].
2.2.3. Cell Invasion Assay
Contrary to the other compounds, only the OS-EPS 15 kDa derivative inhibited the invasiveness
of osteosarcoma cells with a inhibition rate close to 90% after 24 h (Figure 3A). This effect was observed
for both mouse POS-1 and human HOS at a concentration of 25 µg/mL (Figure 3B). OS-EPS 4 kDa and
8 kDa had no effect up to 200 µg/mL (highest concentration tested).
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Figure 3. Invasion of the osteosarcoma cell lines, the mouse POS-1 and human HOS, in the presence of
OS-EPS derivatives with various molecular weights: 25 µg/mL OS-EPS 15 kDa (GYS15), 50 µg/mL
OS-EPS 8 kDa (GYS8), 50 µ /mL OS-EPS 4 kDa (GYS4), 50 µg/mL heparin (Hep) and control (CT).
(A) Microscopic photo raphs f invasive HOS c lls treated or not with f GYS15 or heparin; (B) Cells
migrating through the Boyden’s chambers were counted in five microscopic fields using Image J
software. N.S.: not statistically significant; * p < 0.05; *** p < 0.01.
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2.2.4. Cell Cycle Analysis
At the concentration of 300 µg/mL, the OS-EPS 15 kDa derivative had no significant effect on the
cell cycle of both mouse POS-1 and human HOS (Figure 4). In addition, heparin also had no effect
on the cell cycle at the same concentration (data not shown). Similar data were obtained after 72 h of
treatment (data not shown).
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derivative can be explained by the alteration of protease regulation [23]. This dysregulation of protease
expression may be also favor inhibition of tumor apoptosis [24,25].Molecules 2016, 21, 309 6 of 13 
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Figure 5. Effect of OS-EPS 15 kDa derivative on the expression of MMP-2 and MMP-9 and their
inhibitors (TIMP-1 and TIMP-2, respectively) compared to heparin on human HOS cell line. The
osteosarcoma cells were treated 1, 3, 6, 8 and 24 h with OS-EPS 15 kDa derivative or heparin at the
concentration of 50 µg/mL or not (control). The cell expression of MMPs and their inhibitors in
osteosarcoma cells was determined by RT-qPCR. ** p < 0.01.
2.3. In Vivo Studies
2.3.1. Primary Malignant Bone Tumor Growth
A curative treatment was performed on mouse model (paratibial model) of osteosarcoma induced
by inoculation of mouse POS-1 or human HOS cell line. The treatment started when the tumor volume
reached 100 mm3 (Day 0) and the mice were divided in three groups: 1—treated with PBS (control);
2—treated with OS-EPS 15 kDa derivative; and 3—treated with heparin. The polysaccharides were
injected subcutaneously (50 µL) each day at 2 or 6 mg/kg and the tumor growth was measured from
Day 5 to Day 9. Mouse body weights, measured twice a week, were equivalent in the three groups
studied, demonstrating that polysaccharides had no impact on the body weight (data not shown). Both
polysaccharides were not able to inhibit primary tumor growth in preclinical osteosarcoma mouse
models. These results demonstrated that both OS-EPS 15 kDa derivative and heparin had no effect on
the primary osteosarcoma tumor induced by either mouse POS-1 cell line (Figure 6) or by human HOS
cell line (Figure 6). OS-EPS derivative had no pro-apoptotic effect on osteosarcoma cells as analyzed
by terminal deoxynucleotidyl transferase dUTP nick end labeling staining (TUNEL) (Supplementary
Figure S1). This result is an agreement with the increase of TIMP-1 expression after OS-EPS stimulation,
which can protect cancer cells from death [24,25].
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Figure 6. Effect of OS-EPS 15 kDa derivative on the in vivo HOS osteosarcoma tumor growth:
2 ˆ 106 HOS cells were inoculated in paratibial area. When tumor volume reached 100 mm3, OS-EPS
15 kDa (2 or 6 mg/kg daily) was injected subcutaneously each day and the tumor growth was measured
from Day 5 to Day 30.
2.3.2. Model of Lung Metastases from Mouse Osteosarcoma
A preventive treatment was establish to study the effect of OS-EPS 15 kDa derivative on the
metastatic ability of osteosarcoma by the technique of retro-orbital injection of the venous sinus in
mice [23]. In this experiment, mice received POS-1 cells, metastases arising within a few weeks
after POS-1 cell injection. OS-EPS 15 kDa derivative treated mice had significantly less metastases
(around 40% of decrease) than the untreated ones or heparin treated ones (p < 0.001) (Figure 7A).
The histological analyses of lung tissue showed that OS-EPS 15 kDa derivative treated mice did not
exhibit the presence of metastatic foci similarly to heparin in contrast to the control group treated
with a vehicle (PBS) (Figure 7C). This lower incidence of detectable lung metastases was accompanied
by an improvement of animal survival rate: 70% of treated animal survived 65 days after the POS-1
cell line injection, whereas only 14% of the control group survived (Figure 7C). As expected, heparin
decreased the incidence of lung metastatic incidence [15,16]. No adverse effect of OS-EPS derivatives
was observed in mice. In addition to heparin [15,16], various polysaccharides were already envisaged
in the treatment of solid cancers [26]. OS-EPS derivatives such as GYS 15 kDa, belongs to these
compound family. Recently, a polysaccharide isolated from Prunella vulgaris L. (PV), a plant often
utilized in traditional Chinese medicine, showed antitumor activity in a pre-clinical model of lung
adenocarcinoma [8]. GYS 15 kDa exhibits anti-metastatic activity and its low efficiency in clotting
assays [13,14], is clearly an added therapeutic value. OS-EPS effect on metastatic process may also
be strengthened by the increase of TIMP-1 expression, which was shown to enhance tumor kinetic
and angiogenesis and was also responsible for the creation of premetastatic niche by immune cell
recruitment. Numerous hypotheses can be proposed to explain the effects of heparin in absence of
effect on cell migration and invasion [27,28]. Among these hypotheses, TRAIL (TNF Related Apoptosis
Inducing Ligand) is spontaneously produced by immune cells in response to tumor invasion and to
kill cancer cells. TRAIL activities can be blocked by osteoprotegerin (OPG) which is produced by
tumor cells [29]. Therein, OPG can act as an anti-apoptotic and a pro-proliferative factor for cancer
cells by blocking TRAIL activity in the control group [30]. However, OPG possesses a heparin-binding
domain which is known to regulate OPG and glycoaminoglycans and proteoglycans are able to inhibit
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OPG activity reinforcing TRAIL activity similarly to the heparin group [31]. Overall, activity levels
observed of OP-EPS and heparin can be explained by their differential affinities to OPG and other
proteins with heparin-binding domain.Molecules 2016, 21, 309 8 of 13 
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3. Experimental Section
3.1. General
The bacterial GY785 EPS as produced, purified and characterized as previously described [32,33].
The preparation, purification and characterization of oversulfated ( S) lo olecular eight
(L ) EPS derivatives (OS-EPS 15 kDa (GYS15), OS-EPS 8 kDa (GYS8) and OS-EPS 4 kDa
(GYS4)) have been reported previously [14,33,34]. Briefly, native high molecular weight (HMW)
GY785 EPS was depolymerized first using a free-radical depolymerization process to obtain LMW
derivatives at different molecular weights. LMW GY785 EPS derivatives were therefore sulfated in
di ethylformamide (DMF) using pyridine sulfate as sulfating agent leading to OS EPS derivatives.
olecular eight (MW) before and after sulfation was determined by HPSEC-MALS and sulfur content
(wt % S) by both elemental analysis and HPAEC chromatography. ATR-FTIR and NMR spectroscopy
were used to assess the efficiency of sulfation reaction. Heparin sodium salt from porcine intestinal
mucosa H4784 was purchased from Sigma.
3.2. Proliferation A say
POS-1 ce l line was cultured in RPMI (Roswe l Park Memorial Institute, Biowhi taker, Castleford,
UK) ediu ith 10 f tal i e r , l , ). S/NP (HOS, (ATCC, Mana sas,
, )) as c lt re in E ( ulbecco’s odified Eagle Medium, Biowhi taker) with 5% FBS.
The ce ls, initially s eded a the concentration of 50 ˆ 103 cellules/cm2, were incub ed at 37 ˝C
Molecules 2016, 21, 309 9 of 13
with humidity saturated controlled atmosphere and 5% CO2. At confluence, cells were detached
with trypsine-EDTA (Biowhittaker, Trypsine: 0.5 g/L; EDTA (Ethylene Diamine Tetraacetic Acid):
0.2 g/L). Trypsine was neutralized by adding FBS containing medium and cells were collected after
centrifugation at 400 g. POS-1 and HOS cell lines were seeded in triplicate at two thousand cells per
well in a 24-well plate with 500 µL of medium and treated in the presence of OS-EPS 4, 8 or 15 kDa
derivative (25, 50 ou 100 µg/mL) or not (control). Proliferation assays were performed by manual
counting of alive cells using a Malassez cell with Trypan Blue to compare the cell proliferation rate
between groups.
3.3. Migration Assay
Cells seeded (4 ˆ 105) in 6-well plates in duplicate were treated with mitomycin C (4 µg/mL
during 1 h, Sigma Aldrich, Saint Quentin Fallavier, France) to block cell proliferation and the migration
of cells was evaluated in the presence or not of OS-EPS 4, 8 or 15 kDa derivative or heparin (25 or
50 µg/mL). At confluence, cells were carefully scratched with the tip to create a gap. Cells Images of
the gap width were acquired using an Olympus DP12-2 camera (Olympus Corporation, Tokyo, Japan)
after 0, 24, 48 and 72 h of incubation.
3.4. Invasion Assay
Invasion of cultured cells (POS-1 and HOS) was analyzed using Boyden’s chambers (8 µm
pores, Becton Dickinson Labware, Le Pont-de-Claix, France) covered by polyethylene terephtalate
membrane with Matrigel® coating (2 µg/100 µL/well in cold PBS) in 24-wells plate (Multiwell™ 24,
FALCON®). The OS-EPS 4, 8 or 15 kDa derivative (25, 50,100 or 200 µg/mL) were added on the
Matrigel 30 min before cell seeding. Cells previously treated with mitomycin C (4 µg/mL during 1 h,
Sigma) were seeded in the upper compartment of 500 µL cups in 1% FBS medium (2ˆ 104 POS-1 cells or
3 ˆ 104 HOS) and left 24 h for incubation at 37 ˝C in 5% CO2 humidified atmosphere. The bottom
wells in the system were filled with 10% FBS medium (700 µL) as a chemoattractant. At the end of
the 24 h-period, non-invasive cells were removed with cotton swabs and invading cells present on
the inferior surface of the membrane were fixed by 3% PFA (ParaFormAldehyde) and stained by
methylene blue. After drying, the invasive cells were counted in 5 microscopic fields using Image J
software (version 1.49, NIH, Bethesda, MD, USA). All experiments were done 3 times in duplicates
and invasion is expressed by mean number of cells/field.
3.5. Cell Cycle Analysis
Cells were incubated for 24, 48 or 72 h in medium containing or not containing OS-EPS derivatives.
Cells were incubated during 24, 48 or 72 h in medium containing or not containing OS-EPS derivatives.
After the incubation period, trypsinized cells were incubated in phosphate-buffered saline containing
0.12% Triton X-100, 0.12 mmol/L ethylenediamine tetraacetic acid, and 100 µg/mL DNase-free RNase
A (Sigma). Then, 50 µg/mL propidium iodide were added, and the cells were incubated for 20 min at
4 ˝C in the dark. Cell cycle distribution was studied by flow cytometry (Cytomics FC500; Beckman
Coulter, Roissy, France) based on 2N and 4N DNA content and analyzed using DNA Cell Cycle
Analysis Software (version 306, Phoenix Flow Systems, San Diego, CA, USA) [18].
3.6. Matrix Metalloproteinase Expression
Cells were seeded (5 ˆ 105) in petri dishes (diameter of 60 mm) in 3 m of medium with FBS. At
confluence, cells were treated 1, 3, 6, 8 and 24 h with OS-EPS 15 KDa derivative or heparin at 50 µg/mL
or with PBS (control). Matrix Metalloproteinase (MMP) and Tissue Inhibitors of Metalloproteinase
(TIMP) expression was determined by quantitative-polymerase chain reaction (qPCR). RNA was
extracted using NucleoSpin RNAII (Macherey Nagel, Duren, Germany) and used for first strand
cDNA synthesis using ThermoScript real-time polymerase chain reaction (RT-PCR) System (Invitrogen,
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Carlsbad, CA, USA). Quantitative-PCR (qPCR) was performed with a Chromo4 instrument (Biorad,
Richmond, CA, USA) using SYBR Green Supermix reagents (Biorad).
3.7. Animal Ethics
All procedures involving animals were conducted in accordance with the Directive 2010/63/EU
of the European Parliament and the Council of the 22/09/2010 on the protection of animals used
for scientific purposes. The protocols presented in this study were approved by the French ethics
committee (CEEA PdL. 06) with the protocol number 2010.34 and under the supervision of the
authorized investigators. Four-week-old male NMRI-Nude mice (n = 6) and four-week-old male
C3H/HeN mice (n = 7) from Elevages Janvier (Le Genest Saint Isle, France) were maintained under
pathogen-free conditions at the Experimental Therapy Unit (Faculty of Medicine, Nantes, France)
in accordance with the institutional guidelines of the French Ethics Committee (CEEA Pays de
la Loire—06).
3.8. Osteosarcoma Mouse Model
Four-week-old male NMRI-Nude mice (n = 6 per group) were anaesthetised by inhalation of an
isoflurane/airmixture (1.5%, 1 L/min) before receiving an intramuscular injection of 2 ˆ 106 HOS cells
in the paratibial area (in 50 µL pf PBS buffer) [35]. Similarly, 1.5ˆ 106 POS-1 cells (n = 6 per group) were
inoculated in four-week-old female C57BL/6 mice [36]. Tumors appeared at the injection site 8 days
later. Tumor volume (V) was calculated from the measurement of two perpendicular diameters using
a caliper, according to the following formula: V = 0.5 ˆ L ˆ (S)2, in which L and S are, respectively,
the largest and smallest perpendicular tumor diameters. A curative protocol was performed, when
the tumor volume reached 100 mm3 mice were treated with PBS (control) or OS-EPS derivatives. We
randomized mice into different groups by tumor volume. The polysaccharides diluted in PBS buffer
(50 µL) were injected subcutaneously each day at 2 or 6 mg/kg and the tumor growth was measured
from Day 5 to Day 35. This mouse model (paratibial model) was chosen rather than the model using
the injection of tumor cells directly into the tibia (intratibial model) because bone lesions were very
similar at the end of the experiment in the two models and because the results are more reproducible in
the first model (paratibial model). In addition, this model mimics the bone lesions observed in human.
3.9. Lung Metastasis Mouse Model
To study the effect of OS-EPS derivatives on the metastatic ability of osteosarcoma,
1.5 ˆ 105 POS-1 cells were injected by the technique of retro-orbital injection of the venous sinus [26].
Mice were anesthetized by inhalation of a combination isoflurane/air (1.5%, 1 L/min) and they
received buprenorphine after the tumor cell injection (0.05 mg/kg; Temgesic®, Schering-Plough).
A preventive protocol was established with four-week-old male C3H/HeN mice (n = 7 per group)
divided into 3 groups: PBS, heparin and OS-EPS 15 kDa. A first subcutaneous injection (12 mg/kg
of OS-EPS derivative or heparin in 50 µL of PBS) was performed 30 minutes before the POS-1 cell
injection. Then, 4 subcutaneous injections were done daily at 6 mg/kg for the derivative or heparin.
Mice were euthanized when mice showed signs of lung metastases development (respiratory distress,
weakness, weight loss, and dorsal kyphosis). Lungs were collected for histological and macroscopic
analysis: the lungs were categorized according to the size (big or small) of the metastases.
3.10. Statistical Analysis
All in vitro experiments were realized 3 times. Numbers of cells per field mean counts were
compared by a non-parametrical Wilcoxon test. Mean tumor volumes were compared using
Kruskal-Wallis test. The size of lung metastases categorical variable was analyzed by Fisher’s exact
test. The difference was considered significant at p < 0.05.
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4. Conclusions
Osteosarcoma is a rare malignant tumor of bone with dramatic clinical outcome. Indeed, lung
metastases are frequent in the history of the diseases and are associated with a very high level of
mortality. Polysaccharides are known to modulate numerous cell functions especially cell adhesion
and migration and may be potentially interesting therapeutic approaches for treating patients suffering
from cancers. In the present manuscript, we demonstrated the therapeutic interest of three oversulfated
low molecular weight marine bacterial exopolysaccharides (OS-EPS). With their low efficiency in
clotting assays and their ability to reduce the in vitro invasiveness of osteosarcoma cells as well as the
metastatic process, OS-EPS represent new class of polysaccharides with high interest in oncology. In
our study, only the OS-EPS 15 kDa derivative could effectively inhibit both migration and invasiveness
of osteosarcoma cells in vitro. Moreover, the OS-EPS 15 kDa derivative was very efficient at inhibiting
the establishment of lung metastases in vivo. Such polysaccharides could also be useful for developing
new delivery systems for conventional chemotherapeutic agents, even if their mechanism of action is
not yet known [37].
Supplementary Materials: Supplementary materials can be accessed at: http://www.mdpi.com/1420-3049/21/
3/309/s1.
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